Full-Time

Business Development Representative; Biologics Development

Curia

Curia

1,001-5,000 employees

End-to-end drug development and manufacturing

Compensation Overview

$105k - $200k/yr

Remote in USA

Remote

Category
Business & Strategy (1)
Required Skills
Sales
Biochemistry
Requirements
  • BS, MS or PhD required, in Biology, Biochemistry, or another related scientific discipline
  • 3+ years of experience in sales or leadership experience in biologics development and manufacturing business sectors
  • Demonstrated experience in CDMO industry
  • Strong commercial and negotiating skills
  • 50% travel is required
  • Must pass a background check
  • Must pass a drug screen
  • May be required to pass Occupational Health Screening
Responsibilities
  • Work closely with the Head of Business Development, Biologics Development to establish the commercial strategy for the territory, define and achieve agreed upon goals, actions and budgets for the Region
  • Provide complex development solutions to Pharmaceutical and Biotech customers in the Biologics space
  • Ensure that existing accounts are serviced effectively, liaise communication, and establish new accounts by planning and organizing daily work schedule to call on potential clients
  • Generate new business leads. Utilize strong interpersonal skills when negotiating contracts and/or bids and building long-term relationships with potential external partners and/or customers
  • Call on prospective accounts, provide technical and administrative information, coordinate presentations, and support proposal generation. Prepare client-specific presentations and other data to respond to client needs
  • Work with internal teams to translate client needs and expectations into reality
  • Monitor competition by gathering current marketplace information on pricing, discovery services, new services, scientific demands, merchandising techniques, etc.
  • Attend various conferences within the region and beyond to support generating business
  • Assist the Head of Business Development, Biologics Development in identifying market potential by evaluating client requirements, defining market, competitors’ share, and competitors’ advantages and weaknesses, forecasting projected business, establishing targeted Company share
  • Perform other duties as may be reasonably assigned in the course of business
Desired Qualifications
  • Significant commercial experience in the biologics development industry, combining sales and marketing skills with a track record in the successful closure of licensing deals and a demonstrable network of contacts within the customer community worldwide
  • Broad and deep understanding of the pharmaceutical and biotech markets and decision-making dynamics within the companies operating in this space

Curia is a contract development and manufacturing organization (CDMO) that partners with pharmaceutical and biotech companies to move medical breakthroughs from concept to market. It provides end-to-end services across the drug development lifecycle, including early research, method development and validation, preformulation, material science, solid-state chemistry, and package device testing. Revenue comes from service contracts for specialized capabilities and expertise, with clients ranging from small startups to large pharma. Curia also collaborates with industry leaders to advance continuous flow development and manufacturing programs. The company differentiates itself through flexible and scalable solutions, deep scientific expertise, and state-of-the-art technology that help clients accelerate development timelines while navigating discovery to commercialization. Its goal is to enable efficient, reliable progression of drug candidates from conception through to market approval.

Company Size

1,001-5,000

Company Stage

Debt Financing

Total Funding

$1.1B

Headquarters

Albany, New York

Founded

1991

Simplify Jobs

Simplify's Take

What believers are saying

  • Biologics segment expansion under Steve Lavezoli accelerates high-margin pharmaceutical outsourcing revenue growth.
  • Carterra partnership positions Curia to capture Pacific Northwest biotech demand in antibody discovery services.
  • Gerald Auer's CFO appointment signals M&A activity and potential strategic initiatives enhancing shareholder value.

What critics are saying

  • Pace Life Sciences acquisition of New Jersey lab erodes Curia's analytical testing capacity and revenue.
  • Larger CDMOs like Lonza and Catalent undercut Curia on biologics capacity, stealing biotech contracts.
  • FDA scrutiny on srRNA manufacturing defects from Replicate Bioscience Phase 1 triggers potential client exodus.

What makes Curia unique

  • Pioneer in self-replicating RNA manufacturing, demonstrated through Replicate Bioscience Phase 1 clinical trial support.
  • Integrated enzymatic doggybone DNA technology via Touchlight collaboration expands mRNA manufacturing competitive advantages.
  • End-to-end CDMO services from discovery through cGMP manufacturing differentiate Curia from specialized competitors.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Curia who can refer or advise you

Benefits

Paid Vacation

401(k) Retirement Plan

401(k) Company Match

Tuition Reimbursement

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
The Carlyle Group
Jan 30th, 2026
AMRI Announces Completion of Acquisition by The Carlyle Group and GTCR | Carlyle

ALBANY, N.Y. – Albany Molecular Research, Inc. (NASDAQ:AMRI), a global contract research, development and manufacturing organization working with the life sciences industry to improve patient outcomes and quality of life for more than 25 years, today announced the completion of its previously announced acquisition by affiliates of The Carlyle Group (“Carlyle”) and affiliates of GTCR LLC (“GTCR”). President and Chief Executive Officer William S. Marth will continue to lead AMRI.

BERNAMA
May 10th, 2024
BIOLOGICS SYMPOSIUM: CURIA, CARTERRA PARTNER TO ADVANCE BIOTECH RESEARCH IN PACIFIC NORTHWEST

KUALA LUMPUR, May 10 (Bernama) - Curia, a contract research, development and manufacturing organisation (CDMO) has announced a partnership with Carterra Inc in hosting a high-throughput biologics symposium slated for May 31, in Seattle, Washington.

PharmiWeb.com
Mar 14th, 2024
Pace® Life Sciences Acquires New Jersey Laboratory From Curia

Former Whitehouse Analytical Laboratory is Now Part of the Pace® Laboratory Network

PPI News Agency
Feb 23rd, 2024
Curia Appoints Steve Lavezoli as Vice President, Biologics

ALBANY, N.Y., Feb. 23, 2024 (GLOBE NEWSWIRE) - Curia, a leading contract research, development and manufacturing organization, today announced it has appointed Steve Lavezoli as vice president of biologics effective Feb. 26.

Cameroon Online News
Feb 5th, 2024
Curia Receives 2024 CDMO Leadership Award

Curia was awarded based on the feedback of respondents in the Small Pharma category.